Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

TARGET-NASH: One-third of NAFLD, NASH patients lost weight, but not all kept it off

Key clinical point: About one-third of overweight patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis slimmed down after a weight-loss intervention, but about 20% gained weight back.

Major finding: About 34% of patients had 5% or more weight loss, while 20.2% regained weight back up to baseline or greater over about 2 years of follow-up.

Study details: A report from the ongoing prospective, observational TARGET-NASH study including 2,037 nonalcoholic fatty liver disease or nonalcoholic steatohepatitis patients with a body mass index of at least 25 kg/m2.

Disclosures: The study is sponsored by TARGET PharmaSolutions. Dr. Malespin reported disclosures with Gilead (speaker board), Intercept (speaker board, advisory committee), and TARGET PharmaSolutions (research grant paid to institution).

Citation:

Malespin MH et al. The Liver Meeting 2019, Abstract 240.